Causality and preventability assessment of adverse drug reactions and adverse drug events of antibiotics among hospitalized patients: A multicenter, cross-sectional study in Lahore, Pakistan

Sadia Iftikhar1, Muhammad Rehan Sarwar1,2,*, Anum Saqib2, Muhammad Sarfraz2,3

1 Akhtar Saeed College of Pharmaceutical Sciences, Lahore, Pakistan, 2 Department of Pharmacy, The Islamia University of Bahawalpur Bahawalpur, Punjab, Pakistan, 3 College of Pharmacy, Al Ain University of Science and Technology, Al Ain, Abu Dhabi, UAE

☯ These authors contributed equally to this work.
* rehansarwaralvi@gmail.com

Abstract

Background and objectives
Adverse drug events (ADEs) are the fifth leading cause of death and thus responsible for a large number of hospital admissions in all over the globe. This study was aimed to assess the antibiotics associated preventability of ADEs and causality of adverse drug reactions (ADRs) among hospitalized patients.

Methods
A prospective, cross-sectional, observational study was conducted in four tertiary care public sector hospitals of Lahore, Pakistan. Study population consisted of hospitalized patients who were prescribed with one or more antibiotics. Data were collected between 1st January, 2017 and 31st June, 2017 from 1,249 patients (384 patients aged ≤ 18 years and 865 patients aged > 18 years). Schumock and Thornton scale was used to assess the preventability of the ADEs. Medication errors (MEs) that caused preventable ADEs were assessed by MEs tracking form while Naranjo score was used to evaluate the causality of ADRs among hospitalized patients.

Results
2,686 antibiotics were prescribed to 1,249 patients. Among them, fluoroquinolones (11.8%), macrolides (11.6%) and cephalosporins (10.9%) were the most frequently prescribed antibiotics. The most affected organ system by antibiotics associated ADEs was gastrointestinal tract. A total of 486 ADEs were found. The preventability assessment revealed that most of the ADEs (58.4%) were preventable (43.6% of the ADEs were definitely preventable while
14.8% were probably preventable) and caused by MEs including wrong drug (40.1%) and monitoring errors (25.0%), during the stage of physician ordering (22.2%) and patient monitoring (21.1%). The errors were caused due to non-adherence of policies (38.4%) and lack of information about antibiotics (32%). Most of the non-preventable ADEs or ADRs among adults and children were “probable” (35.5%) and “possible” (35.8%), respectively. Logistic regression analysis revealed that ADEs were significantly less among females (OR = 0.047, 95%CI = 0.018–0.121, \( p\)-value = <0.001), patients aged 18–52 years (OR = 0.041, 95%CI = 0.013–0.130, \( p\)-value = <0.001), tuberculosis patients (OR = 0.304, 95%CI = 0.186–0.497, \( p\)-value = <0.001), patients with acute respiratory tract infections (OR = 0.004, 95%CI = 0.01–0.019, \( p\)-value = <0.001) and among the patients prescribed with 2 antibiotics per prescription (OR = 0.455, 95%CI = 0.319–0.650, \( p\)-value = <0.001).

**Conclusion**

According to preventability assessment most of the ADEs were definitely preventable and caused by MEs due to non-adherence of policies and lack of information about antibiotics. The causality assessment of non-preventable ADEs showed that most of the ADRs were probable and possible.

**Introduction**

According to the World Health Organization (WHO), adverse drug reaction (ADR) is defined as “any response to a drug which is noxious, unintended, and may occur at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease [1].” According to the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP), adverse drug events (ADEs) are the injuries that are either related to the dose of the drugs or the medical interventions [2]. Both these definitions have subtle differences; however these are crucial in making decisions during routine clinical practices. ADE is an adverse outcome that occurs after the use of a drug, but which may or may not be linked to use of the drug. Therefore, all ADRs are referred to as ADEs, but that not all ADEs can be considered as ADRs. Medication errors (MEs) are those that occur at any stage during the processing of medication [3]. The medication associated ADRs are mostly responsible for the higher rate of morbidity and mortality. Also, ADRs are ranked as the seventh recurrent cause of mortality because one out of every seventh inpatient experiences ADRs during his stay at the hospital [4]. Findings of a meta-analysis showed that annually 1,00,000 patients die in the USA due to ADRs [5]. According to an estimate of a Swedish study, 3.1% of deaths in the general population (encompassing subjects who died in and outside the hospitals) are due to ADRs [6]. The causality assessment is used to establish a probable relationship between medication and ADRs [7]. The scientific term that encompasses the method of comprehension, recognition and prevention of ADEs is known as pharmacovigilance [8]. The basic purpose of pharmacovigilance is to ensure patient safety by preventing these untoward effects [9]. The identification of ADEs still remains a major challenge for physicians [7]. Similar to developing countries, the prevalence of ADEs is common in developed regions. A study revealed the prevalence rate of ADEs among hospitalized patients of England as 3.2%, Germany as 4.8% and the United States of America (USA) as 5.6% [10]. Adverse drug events (ADEs) are considered as the fifth leading cause of death globally, and their poor monitoring and reporting system has worsen the
situation [11]. In developing countries like Pakistan, the antibiotics are frequently used in the inpatient departments of the healthcare settings. Furthermore, due to physiological and pharmacokinetic variations, antibiotic associated ADEs are common in pediatric and geriatric patients [12]. According to an estimate, almost 50% of the inpatients receive one antibiotic agent during their hospital stay and in 20–30% cases, the use of antibiotics is not therapeutically necessary [13,14]. Most of the ADEs are preventable because they occur as a result of medication errors at any stage of medication processing i.e., prescribing, transcribing, dispensing, administering, adherence, or monitoring a drug [15]. A study conducted in Netherlands reported that ADEs pertaining to medication interventions account for 0.2% per hospital admission [16]. The misuse of antibiotics is a matter of concern because of its association with a number of potentially harmful ADEs which may include end-organ damage, hypersensitivity reactions, and super-infections with various antibiotic-resistant organisms [17–19].

In Pakistan, both public and private sector hospitals lack proper pharmacovigilance system and there is unavailability of data for antibiotic-associated ADEs among hospitalized patients on regional, zonal, and national level. Previously published studies round the globe also lack such estimates. A study conducted by Shehab, et al. reported that 19% patients visited emergency department due to antibiotics-associated ADEs [20]. Inpatients are more likely to experience ADEs due to various inevitable reasons which may include 1) the frequent administration of multiple antibiotics to the hospitalized patients [21] and 2) mostly, the inpatients comprises of pediatrics, geriatrics or patients having various co-morbidities and all these patients have high risk of developing ADEs [22,23].

The detection of antibiotic associated ADEs are essential for patient safety. Although numerous studies have been conducted in other countries except Pakistan to determine the preventability associated with ADEs and causal relation of ADRs with antibiotics but those were either limited to a single class of antibiotics or single infection of bacterial origin [24–27]. Therefore, the present study aims to determine the preventability and the reasons of ADEs along with the causal relationship of ADRs with antibiotics that are commonly administered to the hospitalized patients in Pakistan.

**Methods**

**Study design and settings**

A prospective, cross-sectional, observational study was conducted in four public tertiary care hospitals (Mayo hospital, Jinnah hospital, General hospital, and Services hospital) of Lahore, Punjab province of Pakistan. All the study settings lack pharmacovigilance centers and ADEs registers. The detail description about study settings have been mentioned in S1 Appendix.

**Study population and sample size**

According to latest Pakistani census, the total population living in Pakistan is 201,995,540 [28]. Lahore is the most populous city of Punjab province of Pakistan, with a total population of 11,126, 285 [29]. The study population included the patients of all age groups, admitted in general internal medicine ward and pediatric ward, prescribed with antibiotics on the basis of differential diagnosis for ≥24 hours. All those patients were excluded who had medical history of cardiac diseases, hepatic and renal insufficiencies, ear, nose and throat (ENT) disorders. According to hospitals records, a total of 14,592 patients were admitted in internal medicine and pediatric departments during the 6 months of study period. Among them, 1,249 patients (age range 6 to 52 years) met the inclusion criteria of this study.
Data collection
A data collection form [S2 Appendix] was developed which consisted of seven parts: 1) characteristics of the patients, 2) diagnosis, 3) recommended antibiotics, 4) medication errors, 5) causality assessment by Naranjo score, 6) preventability assessment and 7) the effect of ADRs on organ system (if any). The Anatomical Therapeutic Chemical (ATC) classification system [30] was used for the coding of antibiotics. SPSS version 21.0 was used for calculation of reliability coefficients. Internal consistency was measured by Cronbach’s alpha, while reproducibility was evaluated by using intra-class correlation for each item in the scales, with acceptable values $\geq 0.6$. Calculation for Cronbach’s alpha was set at 0.76 for Schmuck and Thornton scale, 0.74 for ME tracking form, and 0.78 for Naranjo score. A pilot study was undertaken between November and December 2016 for pre-testing the study instrument. Data were collected between 1st January, 2017 and 31st June, 2017 according to the objectives of the study. The investigational team included a medical practitioner, pharmacist and a nurse. A total of 8 investigational teams were made. As there was no heterogeneity in the training of all team members, so they were consistent in the determination of ADEs and ADRs. Two investigational teams were assigned to each hospital; one for internal medicine ward and other for pediatric ward.

The review of medical records was conducted on daily basis until the patients were discharged from the respective ward. This enables the investigators to scrutinize data from pertinent lab reports, physician’s progress notes, patient’s medication records (dose, dosage form, frequency and duration of prescribed antibiotics), physician’s order, multidisciplinary progress notes and discharge summaries. All the sign and symptoms that appeared after the use of antibiotics were also recorded. The teams also participated in ward rounds and checked the presence of any alerts for MEs and ADEs. As the attending physicians and clinical pharmacists were having expertise in the field of pharmacovigilance and antibiotic surveillance, so their opinions were also taken in account before reaching the final decision about the occurrence of ADEs.

Note: In this study ADEs refer to injuries which are either caused by the drug (i.e., ADRs or non-preventable ADEs) or by the use of the therapeutic agents (i.e., medication errors or preventable ADEs) while ADRs refer to the definition given by Edwards and Aronson i.e., unpleasant or harmful reactions that have causal relation with the medicinal product, predict untoward outcomes from future administration and demands withdrawal from therapy, alteration of dosage regimen and specific treatments [31]. British National Formulary was used for confirming the ADRs [32]. MEs are those that occur during the processing of medication i.e., prescribing, transcribing, dispensing, administering, adherence, or monitoring a drug [3]. MEs were identified by using the standard guidelines of Current Medical Diagnosis AND Treatment (CMDT) [33], National Institute of Health and Clinical Excellence (NICE) guidelines [34], British National Formulary (BNF) for children [35] and Infectious Diseases Society of Pakistan (IDSP) guidelines for antibiotic use [36]. Some other definitions of important terminologies have been mentioned in S3 Appendix.

Outcome variables
The outcome variables included causality assessment and preventability assessment. The cases in which ADEs appeared were further analyzed for assessing the preventability by Schumock and Thornton Scale. Medication errors were found by using medication error tracking form among definitely preventable and probably preventable ADEs. Naranjo scale was used for determining the causal relationship between non-preventable ADEs and antibiotics.
Schumock and Thornton scale. The Schumock and Thornton criteria [37] was established for assessing the preventability of ADRs. The modified form of this criterion has been used in various studies [38–40]. It has three sections namely definitely preventable, probably preventable and non-preventable. Section A comprises of five questions while section B has four questions. All the answers are categorized as “Yes” or “No”. ADRs were “definitely preventable” if answer was “yes” to one or more questions in section A. If answers were all negative then we proceeded to section B. ADRs were “probably preventable” if answer was “yes” to one or more questions in section B. If answers were all negative then we proceeded to section C. In Section C the ADRs were non-preventable.

Naranjo scale. The Naranjo Scale was developed by Naranjo and coworkers from the University of Toronto [41] for assessing the likelihood of whether an ADR is due to some particular drug or other factors. This validated tool has been used in multiple studies [42–45]. This scale comprises of 10 questions that are answered “Yes”, “No”, or “Do not know”. Different point values (-1, 0, +1 or +2) are assigned to each answer. Total scores range from -4 to +13; the reaction is considered definite if the score is 9 or higher, probable if 5 to 8, possible if 1 to 4, and doubtful if 0 or less.

Medication error tracking form. This tool was prepared for addressing MEs in hospitals for the California Health Care Foundation Data [46]. It consisted of three sections: 1) patient information, 2) medication order information and 3) medication error categorization. The third section comprised of “medication class”, “categories” and “possible causes” of MEs. It also classified MEs into five categories: A) prescribing, B) transcribing, C) dispensing, D) administering and E) monitoring.

Data analysis
Statistical Package for Social Sciences (IBM Corp. Released 2012. IBM SPSS Statistics for Windows Version 21.0. Armonk, NY: IBM Corp.) and Microsoft Excel (MS Office 2010) were used for data analysis. Descriptive statistics such as frequencies and percentages were used to present the data. Furthermore, logistic regression analysis was performed to figure out the factors associated with ADEs. Results were expressed as Odds Ratio (OR) accompanied by 95% Confidence Intervals (95% CI) and a p-value <0.05 was used for statistical significance of differences.

Ethics approval and consent to participate
The ethical approval was obtained from the Pharmacy Research Ethics Committee (PREC) at Akhtar Saeed College of Pharmaceutical Sciences (Reference: 3-2016/PREC, December 22, 2016). Before conducting the study, permission was granted from the hospital administrators. The purpose and protocols of this study were thoroughly explained to every participant and their verbal consents were obtained. Written consent was not possible for most of the respondents because either they were illiterate or they had problems in reading and/or signing the consent document.

Results
Characteristics of the patients
A total of 1,249 patients were investigated. Among them, 57.3% were male and 69.3% were aged >18 years. 37% patients (n = 462) were prescribed antibiotics for urinary tract infections, 29% (n = 362) for acute respiratory tract infections, and 34% (n = 425) for skin and soft tissue infections (Table 1).
Table 1. Characteristics of patients.

| Characteristics          | Total patients n (%) |
|--------------------------|-----------------------|
| Gender                   |                       |
| Male                     | 716 (57.3)            |
| Female                   | 533 (42.7)            |
| Age                      |                       |
| Adults (>18 years)       | 865 (69.3)            |
| Children (≤18 years)     | 384 (30.7)            |
| Co-morbidities           |                       |
| Diabetes                 | 526 (42.1)            |
| Asthma                   | 424 (33.9)            |
| Tuberculosis             | 137 (11.0)            |
| Cystic fibrosis          | 162 (13.0)            |
| Antibiotic indications   |                       |
| Acute respiratory tract infections | 362 (29.0)   |
| Urinary tract infections | 462 (37.0)            |
| Skin and soft tissue infections | 425 (34.0)   |
| Number of antibiotics prescribed per prescription | |
| 1                        | 229 (18.3)            |
| 2                        | 603 (48.3)            |
| 3                        | 417 (33.4)            |

*Percentages have been calculated with respect to the total sample size (n = 1249)

https://doi.org/10.1371/journal.pone.0199456.t001

Prescribing pattern of antibiotics

A total of 2,686 antibiotics were prescribed among 1,249 patients. Among them, fluoroquinolones (11.8%, n = 316), macrolides (11.6%, n = 311) and cephalosporins (10.9%, n = 292) were the most frequently prescribed antibiotics (Table 2).

Organ system affected by ADEs

Antibiotic associated ADEs were found in 38.9% (n = 486) patients. Overall, the most affected organ system was GIT (adults = 30.1%, children = 38%) as shown in Table 3.

Preventability assessment

More than half (n = 284, 58.4%) of the ADEs were preventable (43.6% of the ADEs were definitively preventable while 14.8% were probably preventable) and less than half (n = 202, 41.6%)

Table 2. Antibiotics prescribed among study population.

| Antibiotics Class | ATC code | Number of patients received antibiotics (n = 1,249) | Number of prescribed antibiotics (n = 2,686) |
|-------------------|----------|-----------------------------------------------------|---------------------------------------------|
| Penicillins       | J01C     | 194 (15.5)                                          | 261 (9.7)                                   |
| Macrolides        | J01FA    | 252 (20.2)                                          | 311 (11.6)                                  |
| Cephalosporins    | J01D     | 223 (17.9)                                          | 292 (10.9)                                  |
| Fluoroquinolones  | J01M     | 291 (23.3)                                          | 316 (11.8)                                  |
| Aminoglycosides   | J01G     | 192 (15.4)                                          | 226 (8.4)                                   |
| Tetracyclines     | J01AA    | 193 (15.5)                                          | 221 (8.2)                                   |
| Lincosamide       | J01FF    | 127 (10.2)                                          | 209 (7.8)                                   |
| Carbapenem        | J01DH    | 106 (8.5)                                           | 234 (8.7)                                   |
| Glycopeptide      | J01XA    | 91 (7.3)                                            | 214 (7.9)                                   |
| Oxazolidones      | J01XX    | 102 (8.2)                                           | 186 (6.9)                                   |
| Imidazole derivatives | G01AF | 113 (9.5)                                           | 216 (8.0)                                   |

* ATC = Anatomical Therapeutic Chemical Classification System

https://doi.org/10.1371/journal.pone.0199456.t002
### Table 3. Effect of antibiotics on organ systems of study participants.

| Antibiotics   | Total ADEs N (%) | Age groups          | Cardiac* N (%) | GIT† N (%) | Ototoxicity‡ N (%) | Hematology§ N (%) | Hepatobiliary∥ N (%) | Renal¶ N (%) | Neurotoxicity** N (%) | Others†† N (%) |
|---------------|------------------|---------------------|----------------|------------|--------------------|-------------------|----------------------|--------------|-----------------------|---------------|
| Penicillins   | 62 (35.6)        | Adults 38 (61.3)    | 0 (0.0)        | 19 (30.0)  | 1 (0.0)            | 2 (5.2)           | 5 (13.2)             | 2 (5.3)      | 4 (10.5)              | 6 (15.8)      |
|               |                  | Children 24 (38.7)  | 0 (0.0)        | 15 (62.5)  | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 0 (0.0)      | 6 (25.0)              | 3 (12.0)      |
| Aminoglycosides | 37 (26.1)        | Adults 26 (70.3)    | 0 (0.0)        | 2 (7.7)    | 6 (23.1)           | 1 (3.8)           | 0 (0.0)              | 9 (34.6)     | 3 (11.5)              | 5 (19.2)      |
|               |                  | Children 11 (29.7)  | 0 (0.0)        | 3 (27.3)   | 5 (45.5)           | 1 (9.1)           | 0 (0.0)              | 2 (18.2)     | 0 (0.0)               | 0 (0.0)       |
| Macrolides    | 61 (59.8)        | Adults 33 (54.1)    | 6 (18.2)       | 8 (24.2)   | 7 (21.2)           | 3 (9.1)           | 4 (12.1)             | 0 (0.0)      | 0 (0.0)               | 5 (15.2)      |
|               |                  | Children 28 (45.9)  | 2 (7.1)        | 10 (35.7)  | 4 (14.3)           | 0 (0.0)           | 5 (17.9)             | 0 (0.0)      | 0 (0.0)               | 7 (25.0)      |
| Cephalosporins| 66 (33.7)        | Adults 41 (62.1)    | 0 (0.0)        | 12 (29.3)  | 0 (0.0)            | 17 (41.5)         | 6 (14.6)             | 3 (7.3)      | 2 (4.9)               | 1 (2.4)       |
|               |                  | Children 25 (37.9)  | 0 (0.0)        | 1 (4.0)    | 0 (0.0)            | 7 (28.0)          | 13 (52.0)            | 3 (12.0)     | 1 (4.0)               | 0 (0.0)       |
| Fluoroquinolones | 61 (67.0)       | Adults 39 (63.9)    | 4 (10.2)       | 1 (2.6)    | 9 (23.1)           | 5 (12.8)          | 14 (35.9)            | 2 (5.1)      | 3 (7.7)               | 1 (2.6)       |
|               |                  | Children 22 (36.1)  | 3 (13.6)       | 7 (31.8)   | 0 (0.0)            | 0 (0.0)           | 1 (4.6)              | 4 (18.2)     | 5 (22.7)              | 2 (9.1)       |
| Tetracyclines | 36 (34.9)        | Adults 23 (63.9)    | 0 (0.0)        | 9 (39.1)   | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 0 (0.0)      | 6 (26.1)              | 8 (34.8)      |
|               |                  | Children 13 (36.1)  | 0 (0.0)        | 10 (76.9)  | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 0 (0.0)      | 0 (0.0)               | 3 (23.1)      |
| Lincosamide   | 26 (26.8)        | Adults 17 (65.4)    | 0 (0.0)        | 13 (76.5)  | 0 (0.0)            | 4 (23.5)          | 0 (0.0)              | 0 (0.0)      | 0 (0.0)               | 0 (0.0)       |
|               |                  | Children 9 (34.6)   | 0 (0.0)        | 6 (66.7)   | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 0 (0.0)      | 0 (0.0)               | 3 (33.3)      |
| Carbapenem    | 34 (36.9)        | Adults 23 (67.7)    | 0 (0.0)        | 11 (47.8)  | 0 (0.0)            | 8 (34.8)          | 4 (17.4)             | 0 (0.0)      | 0 (0.0)               | 0 (0.0)       |
|               |                  | Children 11 (32.3)  | 0 (0.0)        | 5 (45.5)   | 0 (0.0)            | 2 (18.2)          | 4 (36.4)             | 0 (0.0)      | 0 (0.0)               | 0 (0.0)       |
| Glycopeptide  | 37 (44.1)        | Adults 19 (51.4)    | 0 (0.0)        | 4 (21.1)   | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 9 (47.4)     | 0 (0.0)               | 6 (31.6)      |
|               |                  | Children 18 (48.6)  | 0 (0.0)        | 0 (0.0)    | 8 (44.4)           | 7 (38.9)          | 0 (0.0)              | 1 (5.6)      | 0 (0.0)               | 2 (11.1)      |
| Oxazolidones  | 29 (32.2)        | Adults 21 (72.4)    | 0 (0.0)        | 5 (23.8)   | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 9 (42.9)     | 7 (33.3)              | 3 (17.5)      |
|               |                  | Children 8 (27.6)   | 0 (0.0)        | 4 (50.0)   | 0 (0.0)            | 1 (12.5)          | 0 (0.0)              | 0 (0.0)      | 0 (0.0)               | 3 (37.5)      |
| Imidazole derivative | 37 (47.4) | Adults 22 (59.5) | 0 (0.0) | 7 (31.8) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 13 (59.1) | 2 (9.1) |
|               |                  | Children 15 (40.5)  | 0 (0.0)        | 9 (60.0)   | 0 (0.0)            | 0 (0.0)           | 0 (0.0)              | 0 (0.0)      | 0 (0.0)               | 6 (40.0)      |

(Continued)
Table 3. (Continued)

| Antibiotics | Total ADEs N (%) | Age groups | Cardiac* N (%) | GIT† N (%) | Ototoxicity§ N (%) | Hematology§ N (%) | Hepatobiliary||| N (%) | Renal¶ N (%) | Neurotoxicity** N (%) | Others*** N (%) |
|-------------|-----------------|------------|----------------|------------|------------------|------------------|-----------------|-----------|-----------------|-------------------------|------------------------|
| Total       | 486 (38.9)      | Adults 302 (62.1) | 10 (3.3)      | 91 (30.1)  | 22 (7.3)         | 40 (13.3)        | 33 (10.9)       | 25 (8.3)  | 40 (13.2)       | 41 (13.6)                |
| Children 184 (37.9) | 5 (2.7)  | 70 (38.0) | 17 (9.2) | 18 (9.8) | 23 (12.5) | 10 (5.4) | 12 (6.5) | 29 (15.8) |

*QTc ≥440 millisecond (ms) in males or ≥460 ms in females in the absence of preexisting arrhythmias, based on ≥2 electrocardiograms
†Abdominal discomfort, nausea and vomiting associated with antibiotic administration, in the absence of an alternate explanation;
‡the ability of speech discrimination was diminished upon administration of antibiotics;
§Developed in the absence of myelosuppressive drugs and characterized as thrombocytopenia (decrease in platelet count < 150 × 10³/μL), anemia (decrease in hemoglobin level <10 g/dL) and leukopenia (decrease in white blood cells level < 4500 cells/μL);
||Characterized as increase in total bilirubin (>3 mg/dL) or alanine transaminase (>3 times patient’s baseline) or aspartate transaminase (>3 times patient’s baseline) when there was no preexisting hepatobiliary disease;
¶Characterized as high level of serum creatinine i.e. ≥ 1.5 time baseline when there was no preexisting acute kidney injury (e.g. sepsis) or exposure to nephrotoxic drug or intravenous contrast;
**Demonstrated as antibiotic associated toxicity, peripheral neuropathy, seizures (when there was no preexisting neurologic condition) or altered mental condition;
***Other ADRs among children may include penicillins-associated hypersensitivity; macrolides-associated rashes and Stevens-Johnson syndrome; Fluoroquinolones-associated arthralgia and tendon disorders; tetracyclines-associated tooth discoloration and enamel defects; Lincosamide-associated metallic taste; Glycopeptide-associated flushing and maculopapular rash; Oxazolidones-associated red man syndrome, pruritus and oral candidiasis; imidazole-associated taste disturbance. Other ADRs among adults may include penicillins-associated hypersensitivity; aminoglycosides-associated stomatitis; macrolides-associated pancreatitis; cephalosporins-associated Stevens-Johnson syndrome, pruritus and urticaria; Fluoroquinolones-associated hypotension; Tetracyclines-associated rash, dermatitis and angioedema; Glycopeptide-associated red man syndrome and phlebitis; Oxazolidones-associated taste disturbance and polyuria; imidazole-associated taste disturbance and neuropathy.

https://doi.org/10.1371/journal.pone.0199456.t003
were non-preventable ADEs or ADRs according to modified Schumock and Thornton criteria (Table 4).

Among preventable ADEs (58.4%, n = 284), most of the definitely preventable ADEs were found in those patients who received macrolides and cephalosporins, while probably preventable ADEs were found among those who were administered fluoroquinolones and lincosamide. Non-preventable ADEs (41.6%, n = 202) were found among those patients who were prescribed with cephalosporins and fluoroquinolones (Table 5).

**Medication errors**

In all the preventable cases of ADEs (n = 284), the wrong drug errors (n = 114, 40.1%) and monitoring errors (n = 71, 25%) were more commonly found among the study population. Physician ordering (22.2%, n = 63) and patient monitoring (21.1%, n = 60) were the most

---

**Table 4. Preventability assessment.**

| Schumock and Thornton criteria | Adult (n = 302) | Child (n = 184) | Total (n = 486) |
|-------------------------------|----------------|----------------|----------------|
| **Section A: Definitely preventable ADEs** | | | |
| Was there a history of allergy or previous reaction to the drug? | 6 (1.9) | 5 (2.7) | 11 (2.3) |
| Was the drug involved inappropriate for the patient’s clinical condition? | 49 (16.2) | 26 (14.1) | 75 (15.4) |
| Was the dose, route, or frequency of administration inappropriate for patient’s age, weight or disease state? | 39 (12.9) | 23 (12.5) | 62 (12.8) |
| Was toxic serum drug concentration or lab monitoring test documented? | 27 (8.9) | 13 (7.1) | 40 (8.2) |
| Was there a known treatment for ADEs? | 13 (4.3) | 11 (5.9) | 24 (4.9) |
| **Total** | **134 (44.4)** | **78 (42.4)** | **212 (43.6)** |

| **Section B: Probably preventable ADEs** | | | |
| Was therapeutic drug monitoring or other necessary lab test not performed? | 28 (9.3) | 4 (2.2) | 32 (6.6) |
| Was the drug interaction involved in ADEs? | 7 (2.3) | 5 (2.7) | 12 (2.5) |
| Was poor compliance involved in ADE? | 8 (2.7) | 9 (4.9) | 17 (3.5) |
| Were preventative measures not prescribed or administered to the patient? | 4 (1.3) | 7 (3.8) | 11(2.3) |
| **Total** | **47 (15.6)** | **25 (13.6)** | **72 (14.8)** |

| **Total (preventable ADEs)** | **181 (59.9)** | **103 (55.9)** | **284 (58.4)** |

| **Section C: Non-preventable ADEs or ADRs** | | | |
| If all the above criteria not fulfilled. | 121 (40.1) | 81 (44.0) | 202 (41.6) |

---

**Table 5. ADEs with respect to class of prescribed antibiotics.**

| Antibiotics | ATC code | Definitely preventable ADEs | Probably preventable ADEs | Non-preventable ADEs |
|-------------|----------|-----------------------------|--------------------------|---------------------|
| Penicillins | J01C     | 15 (11.2) 10 (12.8) 25 (11.8) | 6 (12.8) 3 (12.0) 9 (12.5) | 17 (14.1) 11 (13.6) 28 (13.9) |
| Macrolides  | J01FA    | 17 (12.7) 14 (17.9) 31 (14.6) | 3 (6.4) 1 (4.0) 4 (5.6) | 13 (10.7) 13 (16.1) 26 (12.9) |
| Cephalosporins | J01D     | 20 (14.9) 11 (14.1) 31 (14.6) | 2 (4.3) 4 (16.0) 6 (8.3) | 19 (15.7) 10 (12.4) 29 (14.4) |
| Fluoroquinolones | J01M     | 10 (7.5) 11 (14.1) 21 (9.9) | 11 (23.4) 2 (8.0) 13 (18.1) | 18 (14.9) 9 (11.1) 27 (13.4) |
| Aminoglycosides | J01G     | 12 (8.9) 4 (5.1) 16 (7.5) | 4 (8.5) 2 (8.0) 6 (8.3) | 10 (8.3) 5 (6.2) 15 (7.4) |
| Tetracyclines | J01AA    | 7 (5.2) 6 (7.7) 13 (6.1) | 7 (14.9) 1 (4.0) 8 (11.1) | 9 (7.4) 6 (7.4) 15 (7.4) |
| Lincosamide | J01FF    | 4 (2.9) 1 (1.3) 5 (2.4) | 6 (12.8) 4 (16.0) 10 (13.9) | 7 (5.8) 4 (4.9) 11 (5.5) |
| Carbapenem  | J01DH    | 13 (9.7) 5 (6.4) 18 (8.5) | 1 (2.1) 1 (4.0) 2 (2.8) | 9 (7.4) 5 (6.2) 14 (6.9) |
| Glycopeptide | J01XA    | 9 (6.7) 8 (10.3) 17 (8.0) | 2 (4.3) 2 (8.0) 4 (5.6) | 8 (6.6) 8 (9.9) 16 (7.9) |
| Oxazolidiones | J01XX    | 12 (8.9) 4 (5.1) 16 (7.5) | 3 (6.4) 1 (4.0) 4 (5.6) | 6 (4.9) 3 (3.7) 9 (4.5) |
| Imidazole derivatives | G01AF    | 15 (11.2) 4 (5.1) 19 (8.9) | 2 (4.3) 4 (16.0) 6 (8.3) | 5 (4.1) 7 (8.6) 12 (5.9) |
common stages of medication errors. These errors were mainly caused due to non-adherence of policies and procedures (38.4%, n = 109) and lack of information about antibiotics (32%, n = 91) (Table 6).

### Causality assessment

121 (59.9%) ADEs were detected among adult patients (> 18 years of age) and 81 (40.1%) among children (≤ 18 years of age). Most of the ADRs were “probable” (adults = 35.5%, children = 34.6%) and “possible” (adults = 31.4%, children = 35.8%) (Table 7).

### Difference in ADEs among respondents

Logistic regression analysis examined the association between ADEs and the independent variables. Results of this analysis revealed that females had 95.3% less ADEs (OR = 0.047, 95% CI = 0.018–0.121, p-value = <0.001) as compared to males. Among the age groups, patients aged >18 years (OR = 0.041, 95%CI = 0.013–0.130, p-value = <0.001) were likely to have less ADEs as compared to patients aged ≤18 years. While examining the association between co-morbidities and ADEs, asthmatic patients (OR = 0.808, 95%CI = 0.598–1.093, p-value = 0.167), tuberculosis patients (OR = 0.304, 95%CI = 0.186–0.497, p-value = <0.001) and cystic fibrosis patients (OR = 0.527, 95%CI = 0.334–0.829, p-value = 0.006) were likely to have less ADEs as compared to diabetic patients. According to diagnosis, patients with acute respiratory tract

### Table 6. Antibiotic associated errors in study population.

| Variables                              | Adult (n = 181) | Child (n = 103) | Total (n = 284) |
|----------------------------------------|----------------|----------------|-----------------|
| **Type of medication errors**          |                |                |                 |
| Wrong drug                             | 71 (39.2)      | 43 (41.7)      | 114 (40.1)      |
| Wrong dose                             | 24 (13.3)      | 17 (16.5)      | 41 (14.4)       |
| Wrong route                            | 4 (2.2)        | 1 (0.9)        | 5 (1.8)         |
| Wrong time                             | 11 (6.1)       | 4 (3.9)        | 15 (5.3)        |
| Deteriorated drug                      | 1 (0.6)        | 2 (1.9)        | 3 (1.1)         |
| Omission                               | 9 (4.9)        | 6 (5.8)        | 15 (5.3)        |
| Wrong dosage form                      | 1 (0.6)        | 2 (1.9)        | 3 (1.1)         |
| Non-adherence                          | 8 (4.4)        | 9 (8.7)        | 17 (5.9)        |
| Monitoring error                       | 52 (28.7)      | 19 (18.5)      | 71 (25.0)       |
| **Stages of errors**                   |                |                |                 |
| Physician ordering                     | 36 (19.9)      | 27 (26.2)      | 63 (22.2)       |
| Transcribing                           | 27 (14.9)      | 21 (20.4)      | 48 (16.9)       |
| Dispensing pharmacist                  | 31 (17.1)      | 19 (18.5)      | 50 (17.6)       |
| Nurse administering                    | 32 (17.7)      | 14 (13.6)      | 46 (16.2)       |
| Patient monitoring                     | 47 (25.9)      | 13 (12.6)      | 60 (21.1)       |
| Others†                                | 8 (4.4)        | 9 (8.7)        | 17 (5.9)        |
| **Causes of errors**                   |                |                |                 |
| Lack of knowledge about the patients†  | 32 (17.7)      | 16 (15.5)      | 48 (16.9)       |
| Lack of information about antibiotics‡ | 58 (32.0)      | 33 (32.0)      | 91 (32.0)       |
| Non-adherence to policies and procedures§ | 67 (37.0)   | 42 (40.8)      | 109 (38.4)      |
| Miscellaneous||| 24 (13.3) | 12 (11.7) | 36 (12.7) |

*Medication errors due to patient non-adherence;† information about allergy, lab tests results, concomitant medications and conditions either not available or noted;‡ indication for antibiotic use, compatibility, available dosage form, dosing guidelines and route of administration;§ use of abbreviation in medication ordering, incomplete medication order processed, deviation from treatment protocols, delay in dispensing, use of non-standard dosing schedule, and drug preparation errors;|| illegible handwriting of physicians, memory lapse, and unavailability of drugs.

https://doi.org/10.1371/journal.pone.0199456.t006
infections had 99.6% less ADEs (OR = 0.004, 95%CI = 0.01–0.019, p-value = <0.001) and patients with skin and soft tissue infections had 95.1% less ADEs (OR = 0.49, 95%CI = 0.018–0.133, p-value = <0.001) as compared to the patients having urinary tract infections. Among the number of antibiotics prescribed per prescription, 2 antibiotics prescribed per prescription had 54.5% less ADEs (OR = 0.455, 95%CI = 0.319–0.650, p-value = <0.001) while 3 antibiotics prescribed per prescription had 1.529 times more ADEs (OR = 1.529, 95%CI = 1.063–2.198, p-value = 0.022) as compared to those which had 1 antibiotic prescribed per prescription (Table 8).

Discussion

The current study set out to determine the causality and preventability assessment of antibiotic associated ADEs among hospitalized patients. Findings showed that overall antibiotics associated ADEs were detected in 38.9% of the patients. The definitely preventable ADEs were more commonly found as compared to ADRs. Wrong drug selection was the most commonly found medication error responsible for preventable ADEs. Non-availability of national guidelines and national formularies for pediatric and geriatric population might be the possible causes of these errors [47]. Similar to our results, a study conducted in an Australian tertiary care hospital revealed that inappropriate antibiotic prescribing was the cause of antibiotic associated non-preventable ADEs in 29% of the total reported cases [48]. A study conducted in a tertiary care hospital of Kerala, India, showed that 44.9% of the total ADEs were non-preventable and cephalosporins associated ADRs were responsible for 34.7% of the total cases which affected mostly GIT and skin. Among them 10.2% of the cases were “definite” while 18.4% of the cases were “probable” and “possible” [49]. The high rate of preventable ADEs is due to the facts that

Table 7. Causality assessment with respect to antibiotics class.

| Antibiotics Class | ATC code | Patients > 18 years of age | Naranjo score | Total ADRs | Patients ≤ 18 years of age | Naranjo score | Total ADRs |
|-------------------|----------|-----------------------------|---------------|------------|-----------------------------|---------------|------------|
| Penicillins       | J01C     | 1 (5.9)                     | 10 (58.8)     | 2 (11.8)   | 4 (23.5)                    | 17            | 0 (0.0)    | 5 (45.5)   | 2 (18.2) | 4 (36.4) |
| Macrolides        | J01FA    | 1 (7.7)                     | 3 (23.1)      | 6 (46.2)   | 3 (23.1)                    | 13            | 1 (7.7)    | 2 (15.4) | 7 (53.8) | 3 (23.1) |
| Cephalosporins    | J01D     | 3 (15.8)                    | 7 (36.8)      | 4 (21.1)   | 5 (26.3)                    | 19            | 0 (0.0)    | 1 (10.0) | 6 (60.0) | 3 (30.0) |
| Fluoroquinolones  | J01M     | 2 (11.1)                    | 8 (44.4)      | 5 (27.8)   | 3 (16.7)                    | 18            | 2 (22.2)  | 3 (33.3) | 4 (44.4) | 0 (0.0)  |
| Aminoglycosides   | J01G     | 1 (10.0)                    | 4 (40.0)      | 3 (30.0)   | 2 (20.0)                    | 10            | 1 (20.0)  | 1 (20.0) | 2 (40.0) | 1 (20.0) |
| Tetracyclines     | J01AA    | 2 (22.2)                    | 0 (0.0)       | 4 (44.4)   | 3 (33.3)                    | 9             | 0 (0.0)    | 3 (50.0) | 1 (16.7) | 2 (33.3) |
| Lincomamide       | J01FF    | 1 (14.3)                    | 3 (42.9)      | 1 (14.3)   | 2 (28.6)                    | 7             | 0 (0.0)    | 2 (50.0) | 1 (25.0) | 1 (25.0) |
| Carbenem          | J01DH    | 1 (11.1)                    | 3 (33.3)      | 1 (11.1)   | 4 (44.4)                    | 9             | 0 (0.0)    | 3 (60.0) | 2 (40.0) | 0 (0.0)  |
| Glycopeptide      | J01XA    | 0 (0.0)                     | 2 (25.0)      | 5 (62.5)   | 1 (12.5)                    | 8             | 2 (25.0)  | 3 (37.5) | 1 (12.5) | 2 (25.0) |
| Oxazolidones      | J01XX    | 0 (0.0)                     | 1 (16.7)      | 4 (66.7)   | 1 (16.7)                    | 6             | 0 (0.0)    | 2 (66.7) | 1 (33.3) | 0 (0.0)  |
| Imidazole derivatives | G01AF | 0 (0.0)                    | 2 (40.0)      | 3 (60.0)   | 0 (0.0)                      | 5             | 1 (14.3)  | 3 (42.9) | 2 (28.6) | 1 (14.3) |
| **Total**         |          | 12 (9.9)                    | 43 (35.5)     | 38 (31.4)  | 28 (23.1)                    | 121           | 7 (8.6)   | 28 (34.6) | 29 (35.8) | 17 (20.9) |
clinical pharmacists in Pakistan are not actively participating in ward rounds or prescription evaluations and prescribers do not consider it necessary to report the medication errors [50]. In this study, none of the selected settings had well established pharmacovigilance center. Majority of local masses in Pakistan visit public hospitals but the ADEs reporting system in these healthcare settings is poor. This might be because of the unavailability of ADEs reporting form (e.g., yellow card scheme), low budget allocation by the government for health sector, and high patient load [51].

The most effected organs by both preventable ADEs and ADRs were GIT, kidneys and skin. Similarly, an Indian study revealed GIT as the most effected organ system due to antibiotic associated ADRs [52]. The data from Brazil had revealed that most of the ADRs affected skin (34.5%) and GIT (14.2%), and were found more common in adults (75.8%) as compared to children (7.4%) [53]. Similar to the findings of current study, a retrospective study conducted in pulmonology units of two healthcare settings of Italy had also concluded that 44.9% of the ADRs were due to antibiotics and the most affected organ was GIT [54]. This might be due to the fact that when antibiotics are administered through oral route they suppress the normal flora found in gut and can cause GIT colonization either by pathogenic or non-pathogenic organisms [55,56]. Launching national pharmacovigilance program and a central drugs standard control body under Drug Regulatory Authority of Pakistan (DRAP) can be beneficial for improving the current situation. The prime focus of this program must be the proper analysis of ADEs among inpatient and outpatient departments of both public and private healthcare settings of Pakistan. Both, federal and provincial governments must make it compulsory for healthcare professionals to report ADEs in the pharmacovigilance centers. The reports from the regional and zonal pharmacovigilance centers will be helpful in making statistical analysis of the ADEs and send these statistics to the WHO Uppsala Monitoring Centre (UMC) in Sweden.

Most of the ADEs were caused by the fluoroquinolones, imidazole derivatives and macrolides. Moreover, most of the non-preventable ADEs or ADRs were “probable” and observed in adult patients as compared to children. This is due to the reason that co-morbidities lead to

| Characteristics         | ADEs | OR     | 95% CI | P-value |
|-------------------------|------|--------|--------|---------|
|                         | Yes  | No     |        |         |
| Gender                  |      |        |        |         |
| Male                    | 293  | 423 (33.9) | 1.0 |        |
| Female                  | 193  | 340 (27.2) | 0.047 | 0.018–0.121 | <0.001 |
| Age                     |      |        |        |         |
| Children (<18 years)    | 184  | 200 (16.0) | 1.0 |        |
| Adults (>18 years)      | 302  | 563 (45.1) | 0.041 | 0.013–0.130 | <0.001 |
| Co-morbidities          |      |        |        |         |
| Diabetes                | 210  | 316 (25.3) | 1.0 |        |
| Asthma                  | 169  | 255 (20.4) | 0.808 | 0.598–1.093 | 0.167 |
| Tuberculosis            | 37   | 100 (8.0) | 0.304 | 0.186–0.497 | <0.001 |
| Cystic fibrosis         | 70   | 92 (7.4) | 0.527 | 0.334–0.829 | 0.006 |
| Antibiotic indications  |      |        |        |         |
| Urinary tract infections| 198  | 264 (21.1) | 1.0 |        |
| Acute respiratory tract infections | 157  | 205 (16.4) | 0.004 | 0.001–0.019 | <0.001 |
| Skin and soft tissue infections | 131  | 294 (23.5) | 0.049 | 0.018–0.133 | <0.001 |
| Number of antibiotics prescribed per prescription |     |        |        |         |
| 1                       | 101  | 128 (10.2) | 1.0 |        |
| 2                       | 153  | 450 (36.0) | 0.455 | 0.319–0.650 | <0.001 |
| 3                       | 232  | 185 (14.8) | 1.529 | 1.063–2.198 | 0.022 |

OR = Odd Ratio, CI = Confidence Interval

https://doi.org/10.1371/journal.pone.0199456.t008
poly-pharmacy, so an ADR could not be attributed to a single drug [57]. This is similar to the study conducted in a tertiary care hospital of North India where causality assessment by Nar- ranjo score had revealed the “probable” ADRs in most of the cases [52]. A prospective study among pediatrics also reported that most of the antibiotics associated ADRs were “probable” and “possible” [58]. Antibiotics are among the most frequently prescribed medicines, and thus may cause the incidence of ADRs to occur at higher rate. Similarly, in a previously published study, fewer ADRs were detected in such healthcare settings where the trend of prescribing antibiotics is infrequent [59]. This is the reason that the guidelines of Centers for Disease Control and Prevention (CDC) does not recommend the physicians to prescribe unnecessary antibiotics especially in hospitalized patients [60]. Moreover the identification of causal association of antibiotics with ADRs helps to prevent iatrogenic complication, therapy optimization and establishment of barriers to prevent the chances of recurrence [61].

Logistic regression analysis showed statistically significant differences among different genders, age groups, co-morbidities, diagnosis and number of antibiotics prescribed per prescription of patients in the study. Less ADEs were found in patients having female gender, >18 years of age, suffering from tuberculosis and acute respiratory tract infections and who were prescribed 2 antibiotics per prescription. Similar to our findings a prospective cross-sectional study revealed directly proportional relation between that ADEs and factors like age and poly-pharmacy [62]. There are various physiological and pharmacological variations among children and adults that cause the therapeutic agents to respond differently among these two age groups [63]. A retrospective study conducted on Chinese pediatric inpatients also showed that occurrence of ADEs was significantly associated with number of drugs but not with other factors like age and gender [64]. This is primarily because of the reason that the risk of drug interactions increases when more number of drugs are prescribed to the patients which leads to the development of ADEs [65]. Similar to findings of previously published studies [66–68], a significant association was found in current study between male gender and ADEs. In contrast to this, other studies depict that antibiotics associated ADEs are more commonly found among females as compared to males [69,70]. While, some studies showed no significant association of ADEs with gender [64,71,72]. This is merely because of the fact that gender differences may not only include biologic differences but other factors like social, cultural, behavioral and physiological dissimilarities have an impact on it [73]. Furthermore, co-morbidities are also attributed as a significant factor for developing ADEs. Findings also suggest that antibiotics associated ADEs were more commonly found among those patients who had diabetes mellitus (DM) as co-morbidity. This might be because of the fact that DM can impair renal functions and negatively affects the metabolism of drugs which makes the patients more prone towards the development of ADEs [74].

This study has some limitations. First, the findings of present study cannot be generalized to entire country; however, since the condition of healthcare sector and pharmacovigilance is similar across the country so it is likely that results are similar for other tertiary care hospitals as well. Second, since it was a cross-sectional study so long term effects of ADEs could not be traced. Future longitudinal studies may address these aspects. The outcomes of treatment interventions like rechallenge and dechallenge were not measured in this study, therefore very few cases were categorized as definite. Also, the Hawthorne effect could have affected the result because physicians, nurses and other paramedical staff were well aware of the study.

**Conclusion**

The present study concluded that the most commonly prescribed antibiotics among hospitalized patients were fluoroquinolones, macrolides and imidazole derivatives. The antibiotic
associated ADEs were common in pediatric patients as compared to adults. The preventability assessment showed that most of the ADEs observed among hospitalized patients were preventable and caused by MEs such as wrong drug and wrong dose errors during the stage of physician ordering and patient monitoring. According to causality assessment most of the non-preventable ADEs or ADRs among adults were probable and among children were possible. The most affected organ system by antibiotics associated ADEs among all age groups was gastrointestinal tract. Furthermore, logistic regression analysis revealed that less ADEs were found in patients having female gender, >18 years of age, tuberculosis disease, acute respiratory tract infections and 2 antibiotics prescribed per prescription. The findings of this study might make the healthcare policy makers aware about the current situation regarding pharmacovigilance system who may take adequate steps for formulating appropriate strategies to prevent the patients from untoward effects of improper use of antibiotics.

Supporting information
S1 Appendix. Characteristics of selected hospitals. (DOCX)
S2 Appendix. Questionnaire of the study. (DOCX)
S3 Appendix. Definitions of different terms. (DOCX)
S1 File. SPSS file. (SAV)

Acknowledgments
We would like to express wholehearted thankfulness to the administration of all the selected settings of Lahore, Pakistan.

Author Contributions
Conceptualization: Muhammad Rehan Sarwar.
Data curation: Sadia Iftikhar, Anum Saqib.
Formal analysis: Sadia Iftikhar, Muhammad Rehan Sarwar, Anum Saqib, Muhammad Sarfraz.
Investigation: Muhammad Rehan Sarwar.
Methodology: Sadia Iftikhar, Muhammad Rehan Sarwar, Anum Saqib, Muhammad Sarfraz.
Project administration: Sadia Iftikhar, Anum Saqib.
Supervision: Muhammad Rehan Sarwar.
Validation: Anum Saqib, Muhammad Sarfraz.
Visualization: Anum Saqib.
Writing – original draft: Sadia Iftikhar, Anum Saqib.
Writing – review & editing: Muhammad Rehan Sarwar, Anum Saqib, Muhammad Sarfraz.
References

1. McDonnell PJ, Jacobs MR (2002) Hospital admissions resulting from preventable adverse drug reactions. Annals of Pharmacotherapy 36: 1331–1336. https://doi.org/10.1345/aph.1A333 PMID: 12196047

2. Prevention NCCfM ERa (2015) Contemporary View of Medication—Related Harm. A New Paradigm.

3. Hepler CD, Segal R (2003) Preventing medication errors and improving drug therapy outcomes: a management systems approach: CRC Press.

4. Wester K, Jonsson AK, Spigset O, Druid H, Hagg S (2008) Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol 65: 573–579. https://doi.org/10.1111/j.1365-2125.2007.03064.x PMID: 18070216

5. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 279: 1200–1205. PMID: 9555760

6. Wester K, Jonsson AK, Spigset O, Druid H, Hägg S (2008) Incidence of fatal adverse drug reactions: a population based study. British journal of clinical pharmacology 65: 573–579. https://doi.org/10.1111/j.1365-2125.2007.03064.x PMID: 18070216

7. Macedo AF, Marques FB, Ribeiro CF, Teixeira F (2005) Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel. pharmacoepidemiology and drug safety 14: 885–890. https://doi.org/10.1002/pds.1138 PMID: 16059869

8. Khan LM, Al-Harthi SE, Saadah OI, Al-Amoudi AB, Sulaiman MI, et al. (2012) Impact of pharmacovigilance on adverse drug reactions reporting in hospitalized internal medicine patients at Saudi Arabian teaching hospital. Saudi Med J 33: 863–868. PMID: 22886119

9. Khan LM, Al-Harthi SE, Saadah OI (2013) Adverse drug reactions in hospitalized pediatric patients of Saudi Arabian University Hospital and impact of pharmacovigilance in reporting ADR. Saudi Pharmaceutical Journal 21: 261–266. https://doi.org/10.1016/j.sjps.2012.09.004 PMID: 23960842

10. Stausberg J (2014) International prevalence of adverse drug events in hospitals: an analysis of routine data from England, Germany, and the USA. BMC Health Serv Res 14: 125. https://doi.org/10.1186/1472-6963-14-125 PMID: 24620750

11. Pathak AK, Kumar M, Dokania S, Mohan L, Dikshit H (2016) A Retrospective Analysis of Reporting of Adverse Drug Reactions in a Tertiary Care Teaching Hospital: One Year Survey. Journal of clinical and diagnostic research: JCDR 10: FC01.

12. Routledge PA, O’mahony M, Woodhouse K (2004) Adverse drug reactions in elderly patients. British journal of clinical pharmacology 57: 121–126. https://doi.org/10.1046/j.1365-2125.2003.01875.x PMID: 14748810

13. Atif M, Azeem M, Sarwar MR, Shahid S, Javaid S, et al. (2016) WHO/INRUD prescribing indicators and prescribing trends of antibiotics in the Accident and Emergency Department of Bahawal Victoria Hospital, Pakistan. SpringerPlus 5: 1928. https://doi.org/10.1186/s40064-016-3615-1 PMID: 27933228

14. Sarwar MR, Saqib A, Iftikhar S, Sadiq T (2018) Knowledge of community pharmacists about antibiotics, and their perceptions and practices regarding antimicrobial stewardship: a cross-sectional study in Punjab, Pakistan. Infection and drug resistance 11: 133. https://doi.org/10.2147/IDR.S148102 PMID: 29403285

15. Pharmacists ASoH-S (1998) Suggested definitions and relationships among medication misadventures, medication errors, adverse drug events, and adverse drug reactions. American Journal of Health-System Pharmacy 55: 165–166. PMID: 9465983

16. Hoonhout LH, de Bruin MC, Wagner C, Asscheman H, van der Wal G, et al. (2010) Nature, occurrence and consequences of medication-related adverse events during hospitalization. Drug safety 33: 853–864. https://doi.org/10.2165/11536800-000000000-00000 PMID: 20812770

17. Atif M, Sarwar MR, Azeem M, Naz M, Amir S, et al. (2016) Assessment of core drug use indicators using WHO/INRUD methodology at primary healthcare centers in Bahawalpur, Pakistan. BMC health services research 16: 684. https://doi.org/10.1186/s12913-016-1932-2 PMID: 27931213

18. Atif M, Sarwar MR, Azeem M, Umer D, Rafi A, et al. (2016) Assessment of WHO/INRUD core drug use indicators in two tertiary care hospitals of Bahawalpur, Punjab, Pakistan. Journal of pharmaceutical policy and practice 9: 27. https://doi.org/10.1186/s40545-016-0076-4 PMID: 27688887

19. Sarwar MR, Atif M, Scabills S, Saqib A, Qamar-uz-Zaman M, et al. (2017) Drug utilization patterns among elderly hospitalized patients on poly-pharmacy in Punjab, Pakistan. Journal of pharmaceutical policy and practice 10: 23. https://doi.org/10.1186/s40545-017-0112-z PMID: 28785413

20. Shehab N, Patel PR, Srinivasan A, Budnitz DS (2008) Emergency department visits for antibiotic-associated adverse events. Clinical infectious diseases 47: 735–743. https://doi.org/10.1086/591126 PMID: 18694344
21. Hammond DA, Smith MN, Li C, Hayes SM, Lusardi K, et al. (2017) Systematic Review and Meta-analysis of Acute Kidney Injury Associated With Concomitant Vancomycin and Piperacillin/Tazobactam. Clinical Infectious Diseases 64: 666–674. https://doi.org/10.1093/cid/ciw811 PMID: 27940946

22. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD (1998) Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. British journal of clinical pharmacology 46: 505–511. https://doi.org/10.1046/j.1365-2125.1998.00817.x PMID: 9833605

23. Pretorius RW, Gataric G, Swedlund SK, Miller JR (2013) Reducing the risk of adverse drug events in older adults. Am Fam Physician 87: 331–336. PMID: 23547549

24. Lin RY, Nuruzzaman F, Shah SN (2009) Incidence and impact of adverse effects to antibiotics in hospitalized adults with pneumonia. J Hosp Med 4: E7–15.

25. Macy E, Contreras R (2015) Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. Journal of Allergy and Clinical Immunology 135: 745–752. e745. https://doi.org/10.1016/j.jaci.2014.07.062 PMID: 25262461

26. Werner NL, Hecker MT, Sethi AK, Donskey CJ (2011) Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect Dis 11: 187. https://doi.org/10.1186/1471-2334-11-187 PMID: 21729289

27. Blumenthal KG, Kuhlen JL, Weil AA, Varughese CA, Kubiak DW, et al. (2016) Adverse drug reactions associated with ceftriaxone use: a 2-center retrospective cohort. The Journal of Allergy and Clinical Immunology: In Practice 4: 740–746. https://doi.org/10.1016/j.jaip.2016.03.008 PMID: 27130709

28. Factbook CW (2017) Population of Cities in Pakistan

29. Review WP (2017) Pakistan Demographics Profile

30. World Health Organization (2006) The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). Oslo: WHO.

31. Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9 PMID: 11072960

32. Committee JF (2016) British National Formulary (online) London: BMJ Group and Pharmaceutical Press. URL: www.medicinescomplete.com (accessed 1 August 2015).

33. McPhee SJ, Papadakis MA, Tierney LM (2010) Current medical diagnosis & treatment 2010: McGraw-Hill Medical New York.

34. Tan T, Little P, Stokes T, Guideline Development G (2008) Antibiotic prescribing for self limiting respiratory tract infections in primary care: summary of NICE guidance. BMJ 337: a437. https://doi.org/10.1136/bmj.a437 PMID: 18650239

35. Committee PF (2014) BNF for children 2014–2015 (BNFC): Pharmaceutical Press.

36. Pakistan TIDSo (2007) Guidelines for the use of antimicrobials. Pakistan.

37. Schumock GT, Thornton JP (1992) Focusing on the preventability of adverse drug reactions. Hosp Pharm 27: 538. PMID: 10118597

38. Padmavathi S, Manimekalai K, Ambujam S (2013) Causality, severity and preventability assessment of adverse cutaneous drug reaction: a prospective observational study in a tertiary care hospital. Journal of clinical and diagnostic research: JCDR 7: 2765. https://doi.org/10.7860/JCDR/2013/7430.3753 PMID: 24551632

39. Kurian J, Mathew J, Sowjanya K, Chaitanya KR, Ramesh M, et al. (2016) Adverse Drug Reactions in Hospitalized Pediatric Patients: A Prospective Observational Study. Indian J Pediatr 83: 414–419. https://doi.org/10.1007/s12098-015-2002-1 PMID: 26916890

40. Doshi K, Yegnanarayan R, Gokhale N (2017) A Retrospective Study of Drug Induced Cutaneous Adverse Reactions (CADR) in Patients Attending a Tertiary Care Hospital. Current drug safety 12: 46–50.

41. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30: 239–245. PMID: 7249508

42. Anderson M, Egunsola O, Cherrill J, Millward C, Fakis A, et al. (2015) A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ Open 5: e008298. https://doi.org/10.1136/bmjopen-2015-008298 PMID: 26033949

43. Sellick J, Mergenhagen K, Morris L, Feuz L, Horey A, et al. (2017) Fluoroquinolone-Related Neuropsychiatric Events in Hospitalized Veterans. Psychosomatics.

44. Trubiano JA, Aung AK, Nguyen M, Fehily SR, Graudins L, et al. (2016) A comparative analysis between antibiotic and nonantibiotic-associated delayed cutaneous adverse drug reactions. The Journal of Allergy and Clinical Immunology: In Practice 4: 1187–1193. https://doi.org/10.1016/j.jaip.2016.04.026 PMID: 27283055
45. Pirhajati Mahabadi V, Nasiripour S, FarasatinaSab M, Nadjafi S (2017) A case of ciprofloxacin-associated Achilles tendinitis. Physiology and Pharmacology 21: 172–174.

46. Sciene P (2001) Addressing Medication Errors in Hospitals—Ten Tools. 47 p.

47. KHALIL SUMAIRA T KM, KHAN HUMA SALEEM (2015) Irrational Use of Antibiotics in Children. Pakistan Pediatric Journal.

48. Trubiano JA, Cairns KA, Evans JA, Ding A, Nguyen T, et al. (2015) The prevalence and impact of antimicrobial allergies and adverse drug reactions at an Australian tertiary centre. BMC Infect Dis 15: 572. https://doi.org/10.1186/s12879-015-1303-3 PMID: 26675619

49. Shamna M, Dilip C, Ajmal M, Linu Mohan P, Shinu C, et al. (2014) A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital. Saudi Pharm J 22: 303–308. https://doi.org/10.1016/j.jsps.2013.06.004 PMID: 25161373

50. Nazir S (2014) Adverse Drug Reaction Reporting System At Different Hospitals Of Lahore-An Evaluation And Patient Outcome Analysis. Value in Health 17: A166.

51. Shami M, Sharib SM, Malhi SM, Munthana S-u, Raza H, et al. (2016) Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. SpringerPlus 5: 1778. https://doi.org/10.1186/s40064-016-3337-4 PMID: 27795920

52. Khan FA, Nizamuddin S, Huda N, Mishra H (2013) A prospective study on prevalence of adverse drug reactions due to antibiotics usage in otolaryngology department of a tertiary care hospital in North India.

53. de Araujo Lobo MGA, Pinheiro SMB, Castro JGD, Momenté VG, Pranevcius M-CS (2013) Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC Pharmacology and Toxicology 14: 5. https://doi.org/10.1186/2050-6511-14-5 PMID: 23298396

54. Gallelli L, Ferreri G, Colosimo M, Pirritano D, Guadagnino L, et al. (2002) Adverse drug reactions to antibiotics observed in two pulmonology divisions of catanzaro, Italy: a six-year retrospective study. Pharmacol Res 46: 395–400. PMID: 12419643

55. Hadjidabbae M, Rastkari N, Rezaiea A, Abdollahi M (2005) The adverse drug reaction in the gastrointestinal tract: an overview. Int J Pharmacol 1: 1–8.

56. Price AB (2003) Pathology of drug-associated gastrointestinal disease. Br J Clin Pharmacol 56: 477–482. https://doi.org/10.1046/j.1365-2125.2003.01980.x PMID: 14651719

57. Kaur S, Kapoor V, Mahajan R, Lai M, Gupta S (2011) Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease. Indian J Pharmacol 43: 22–26. https://doi.org/10.4103/0253-7613.75661 PMID: 21455416

58. Issac AJ, Yogananda R, Shehin M (2016) Assessment of prescription pattern and monitoring adverse drug reaction of antibiotics in pediatric inpatients. International Journal of Contemporary Pediatrics 3: 1071–1075.

59. Kiguba R, Karamagi C, Bird SM (2017) Antibiotic-associated suspected adverse drug reactions among hospitalized patients in Uganda: a prospective cohort study. Pharmacology research & perspectives 5.

60. America IDSo (2008) Adverse Reactions To Antibiotics Send Thousands Of Patients To The ER.

61. Varallo FR, Planeta CS, Herdeiro MT, Mastroianni PC (2017) Imputation of adverse drug reactions: Causality assessment in hospitals. PLoS One 12: e0171470. https://doi.org/10.1371/journal.pone.0171470 PMID: 28166274

62. Silva DC, Araujo OR, Arduini RG, Alonso CF, Shibata AR, et al. (2013) Adverse drug events in a paediatric intensive care unit: a prospective cohort. BMJ Open 3: e001868. https://doi.org/10.1136/bmjopen-2012-001868 PMID: 23427200

63. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, et al. (2003) Developmental pharmacology—drug disposition, action, and therapy in infants and children. New England Journal of Medicine 349: 1157–1167. https://doi.org/10.1056/NEJMra0305092 PMID: 13679531

64. Ji H-h, Song L, Xiao J-w, Guo Y-x, Wei P, et al. (2018) Adverse drug trigger events in Chinese pediatric inpatients and associated risk factors: a retrospective review using the Global Trigger Tool. Scientific reports 8: 2573. https://doi.org/10.1038/s41598-018-20868-2 PMID: 29416072

65. Fushiki Y, Kinoshita K, Tokuda Y (2014) Polypharmacy and adverse drug events leading to acute care hospitalization in Japanese elderly. Journal of General and Family Medicine 15: 110–116.

66. Shamna M, Dilip C, Ajmal M, Mohan PL, Shinu C, et al. (2014) A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital. Saudi pharmaceutical journal 22: 303–308. https://doi.org/10.1016/j.jbps.2013.06.004 PMID: 25161373

67. Jose J, Rao PG, Jimmy B (2008) Adverse drug reactions to fluoroquinolone antibiotics—analysis of reports received in a tertiary care hospital. International journal of risk & safety in medicine 20: 169–180.
68. Mudigubba MK, Rajashekarachari Y, Dahiya S (2017) RISK FACTORS ASSOCIATED WITH ADVERSE DRUG REACTIONS IN HOSPITALIZED PATIENTS. INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH 8: 3847–3854.

69. Hussain MM, Girhepunje K, Pal R, Siddiqua SS (2010) Incidence of adverse drug reactions in a tertiary care hospital: a systematic review and meta-analysis of prospective studies. Der Pharmacia Lettre 2: 358–368.

70. Stavreva G, Pendicheva D, Pandurska A, Marev R (2008) Detection of adverse drug reactions to antimicrobial drugs in hospitalized patients. Trakia J Sci 6: 7–9.

71. Macy E, Ho NJ (2011) Adverse reactions associated with therapeutic antibiotic use after penicillin skin testing. The Permanente Journal 15: 31. PMID: 21841922

72. Muñoz-Torrequillo JFS, Barquilla P, Velasco R, Capitan MdCF, Pacheco, et al. (2010) Adverse drug reactions in internal medicine units and associated risk factors. European journal of clinical pharmacology 66: 1257–1264. https://doi.org/10.1007/s00228-010-0866-6 PMID: 20689943

73. Alomar MJ (2014) Factors affecting the development of adverse drug reactions. Saudi pharmaceutical journal 22: 83–94. https://doi.org/10.1016/j.jsps.2013.02.003 PMID: 24648818

74. Haile DB, Ayen WY, Tiwari P (2013) Prevalence and assessment of factors contributing to adverse drug reactions in wards of a tertiary care hospital, India. Ethiopian journal of health sciences 23: 39–48. PMID: 23559837